Oral presentation

Presentations

Wednesday, 23 November

10:50

Oral presentation

5. Addressing substance use and related problems in reception settings in Europe

10:50 to 12:20

Insights zone 4 (I4)

Charlotte De Kock, Klaudia Palczak

Oral presentation

6. Caregiving packages in conflict and humanitarian settings for prevention of substance use and other health and social consequences and for child protection and development

7. Understanding and Responding to Substance Use and Abuse in the Palestinian Refugee Camps inLebanon Prior to and During COVID-19 Times

10:50 to 12:20

Insights zone 4 (I4)

Marie Claire Van Hout

Oral presentation

3. Handbook on Addressing Substance Use Disorders in Humanitarian Settings – Access to Services for Displaced Populations and Host Communities in Acute and Protracted Emergencies

1. Priorities for addressing substance use disorder in humanitarian settings

2. Substance Use Among Populations Displaced by Conflict: Assessments, Findings, Recommendations

Psychological reactance and adolescent cannabis use: the role of parental warmth and monitoring

Embracing public health approaches to gambling? A review of global legislative and regulatory trends

Attitudes towards alcohol policy in Europe; results of the alcohol survey in 33 European countries

New problems, new approaches: Actions for the case of non-substance addictions for adolescents and young adults

2. Training of trainers package on FAS/FASD prevention

10:50 to 12:20

Central square 1 (C1)

Lidia Segura

Oral presentation

3. Piloting an evidence-based good practice intervention for reducing the risk of FASD

10:50 to 12:20

Central square 1 (C1)

Katarzyna Okulicz-Kozaryn

Oral presentation

1. Guidelines to reduce alcohol consumption in women of child-bearing age

10:50 to 12:20

Central square 1 (C1)

Carla Bruguera

Oral presentation

1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016

10:50 to 12:20

Knowledge market 2 (K2)

Eline Borger Rognli

Oral presentation

2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study

10:50 to 12:20

Knowledge market 2 (K2)

Pihla Sassi

Oral presentation

3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study

10:50 to 12:20

Knowledge market 2 (K2)

Heidi Taipale

Oral presentation

4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections

10:50 to 12:20

Knowledge market 2 (K2)

Jørgen G. Bramness

Oral presentation

5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study

10:50 to 12:20

Knowledge market 2 (K2)

Jeyaniroshan Jeyapalan

Oral presentation

A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies

10:50 to 12:20

Knowledge market 3 (K3)

Carol-Ann Getty

Oral presentation

I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use

10:50 to 12:20

Knowledge market 3 (K3)

Rose Schmidt

Oral presentation

Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada

10:50 to 12:20

Knowledge market 3 (K3)

Stine Hoj

Oral presentation

Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC

10:50 to 12:20

Knowledge market 3 (K3)

Samara Mayer

Oral presentation

Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling

Characterizing habit formation in modern slot machine gambling

A scoping review on cryptocurrency trading among young people and its association with gambling and mental health

Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies

Changes in social work practice and support for people who use drugs during the Covid-19 pandemic – a case study of Malmö, Sweden

10:50 to 12:20

Central square 3 (C3)

Torkel Richert

Oral presentation

2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances

10:50 to 12:20

Knowledge market 1 (K1)

Svetlana Skurtveit

Oral presentation

3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.

10:50 to 12:20

Knowledge market 1 (K1)

Linn Gjersing

Oral presentation

4. Fatal overdoses in a cohort of chronic pain patients

10:50 to 12:20

Knowledge market 1 (K1)

Aleksi Hamina

Oral presentation

Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis

10:50 to 12:20

Central square 2 (C2)

Chrianna Bharat

Oral presentation

Anti-doping knowledge and educational needs of Finnish pharmacists

10:50 to 12:20

Central square 2 (C2)

Jukka Koskelo

Oral presentation

The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)

10:50 to 12:20

Central square 2 (C2)

Emilia Gianola

Oral presentation

Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018

10:50 to 12:20

Central square 2 (C2)

Lonja Schurmann

Oral presentation

Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings

10:50 to 12:20

Central square 2 (C2)

Alexandra Antunes

Oral presentation

Substance Use and Substance Use Disorders in relation to COVID-19: Qualitative Experience of Users in Jordan

10:50 to 12:20

Central square 3 (C3)

Mayyada Wazaify

Oral presentation

Overdose deaths and the COVID-19 pandemic in British Columbia, Canada

10:50 to 12:20

Central square 3 (C3)

Alexis Crabtree

Oral presentation

1. Characteristics of suicides among overdose deaths in Norway in 2016-2020

10:50 to 12:20

Knowledge market 1 (K1)

Hilde Marie Erøy Edvardsen

Oral presentation

Drug use and attitudes toward COVID-19 vaccination in a representative sample of undergraduate students

10:50 to 12:20

Central square 3 (C3)

Stelios Stylianou

Oral presentation

2. Medical use of cannabis and cannabinoids: an overview of evidence

10:50 to 12:20

Knowledge market 4 (K4)

Mafalda Pardal

Oral presentation

5. Treatment of cannabis-related problems in Europe: a typology and evidence overview

10:50 to 12:20

Knowledge market 4 (K4)

Daniel Feingold

Oral presentation

3. Cannabis-related effects and harms: a scientific overview

10:50 to 12:20

Knowledge market 4 (K4)

Jakob Manthey

Oral presentation

4. Harm reduction for cannabis related problems in Europe and beyond

10:50 to 12:20

Knowledge market 4 (K4)

Iciar Indave

Oral presentation

1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms

2. Successful models for implementation of harm reduction programmes

3. How can we improve data and mobilise funding for harm reduction support globally?

4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms

1. Gender-sensitive drug policy

2. Youth-centered drug policy

3. Perspectives of people who use drugs on drug policy

Getting your addiction research published: seminar

10:50 to 12:20

Central square 4 (C4)

Richard Pates

12:20

Oral presentation

Alcohol consumption, impact of COVID-19 and alcohol-attributable disease burden: a global update

12:30

1. Community perspective on access to harm reduction

2. Documenting Egypt’s adoption and upcoming rollout of OAT

3. Introducing the WHO Consolidated guidelines for key populations

4. Introducing the UNODC-WHO OAT Operational tool and training package

12:40

Global alcohol action plan 2020-2030

12:50

European framework for action on alcohol 2022-2025

12:50 to 13:00

Insights zone 4 (I4)

Carina Ferreira-Borges

13:20

Oral presentation

4. The Impact of the Russian Invasion of Ukraine on Needle and Syringe Distribution by Harm Reduction Organizations

1. Equitable substance use treatment for migrants, refugees and ethnic minorities: An emerging research domain

2. Substance use disorders in refugee and migrant groups in Sweden: A nationwide cohort study of 1.2 million people

5. Services for vulnerable Migrants who use Drugs in the EU (SEMID-EU)

3. Smartphone-based addiction prevention for young refugees: results of a feasibility study

13:20 to 14:50

Insights zone 4 (I4)

Lina-Sophia Falkenberg

Oral presentation

1. ABC-Training: A New Proposition-Based Variety of Cognitive Bias Modification. Theoretical Background and Initial Results.

13:20 to 14:50

Central square 1 (C1)

Reinout W. Wiers

Oral presentation

2. Phenotyping Individuals with Alcohol Use Disorder: Implications for Precision Medicine and Predicting Non-Abstinent Recovery from Alcohol Use Disorder

13:20 to 14:50

Central square 1 (C1)

Katie Witkiewitz

Oral presentation

3. Examining a Brief Measure and Observed Cutoff Scores to Identify Reward and Relief Drinking Profiles: Psychometric Properties and Pharmacotherapy Response

13:20 to 14:50

Central square 1 (C1)

Victoria R. Votaw

Oral presentation

Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland

13:20 to 14:50

Knowledge market 3 (K3)

Kirsten Trayner

Oral presentation

The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study

13:20 to 14:50

Knowledge market 3 (K3)

Jack Stone

Oral presentation

The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK

13:20 to 14:50

Knowledge market 3 (K3)

Peter Vickerman

Oral presentation

Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis

13:20 to 14:50

Knowledge market 3 (K3)

Adelina Artenie

Oral presentation

Online gambling and associated harms during the COVID-19 pandemic: A population study

Online gambling and F2P games in Canada: portrait and trends

Problem gambling among European adolescents: potential risk of gambling products and online gambling

Cryptocurrency trading as behavioral addiction: cross-sectional and longitudinal perspective from Finland

5. The U.S. Cannabis Policy Scale: Moving Beyond Dichotomous Measures to Evaluate Impacts of Liberalization Policies on Cannabis and Other Substance Use Outcomes

13:20 to 14:50

Knowledge market 1 (K1)

Rosalie Pacula

Oral presentation

2. Measuring the impacts of a new cannabis regulation in Luxembourg: the need for valid data collection methods

13:20 to 14:50

Knowledge market 1 (K1)

Nadine Berndt

Oral presentation

3. The Swiss pilot trials with cannabis – evaluation after one year

13:20 to 14:50

Knowledge market 1 (K1)

Maya Ackermann

Oral presentation

4. The Dutch closed cannabis supply chain experiment: background, design of the evaluation study and challenges

13:20 to 14:50

Knowledge market 1 (K1)

Margriet van Laar

Oral presentation

1. Prevention Science and the Professionalization of Prevention Practice

3. Training the Prevention Workforce-Future Prevention Workforce

2. International Credentialling

Digital technologies to prevent drug overdoses. A UK perspective

13:20 to 14:50

Central square 3 (C3)

Alberto Oteo

Oral presentation

Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine

13:20 to 14:50

Central square 3 (C3)

Krista Siefried

Oral presentation

2. Design and Testing of an Aftercare Mobile App for Substance Use Among Young Adults: An Interdisicplinary Approach in Denmark

13:20 to 14:50

Insights zone 2 (I2)

Adriana del Palacio-Gonzalez

Oral presentation

3. A guided digital intervention to reduce cannabis use: the ICan randomized controlled trial in the Netherland

4. Boozebuster: A Mobile Intervention to Promote Low-Risk Drinking Habits in Young Adults –preliminary results

1. Guided smartphone-based treatment for patients in opioid maintenance treatment in Iran -transdiagnostic treatment for substance use and common mental disorders

1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services

13:20 to 14:50

Central square 2 (C2)

Joseph Tay Wee Teck

Oral presentation

3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives

13:20 to 14:50

Central square 2 (C2)

Simon Langener

Oral presentation

Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT

13:20 to 14:50

Central square 3 (C3)

Kristien Coteur

Oral presentation

A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study

13:20 to 14:50

Central square 3 (C3)

Katrina Champion

Oral presentation

5. Estimating the costs of the criminal justice system

13:20 to 14:50

Knowledge market 4 (K4)

Francesco Fabi

Oral presentation

1. Overview of the updated ECDC/EMCDDA guidance on the prevention and control of infectious diseases among people who inject drugs

13:20 to 14:50

Networking zone 3 (N3)

Anne Bergenstrom, Janelle Sandberg

Oral presentation

2. Effectiveness of drug treatment, needle and syringe programmes and drug consumption rooms in the prevention of blood-borne viruses among people who inject drugs – updated evidence from reviews of empirical and mathematical modelling studies

13:20 to 14:50

Networking zone 3 (N3)

Matthew Hickman

Oral presentation

3. Enhancing the HCV care cascade among people who inject drugs: a systematic review and considerations from an expert panel

13:20 to 14:50

Networking zone 3 (N3)

Ilonka Horváth

Oral presentation

1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018

13:20 to 14:50

Knowledge market 4 (K4)

Carla Rossi

Oral presentation

2. Hospitalization risk profile of opioids users

13:20 to 14:50

Knowledge market 4 (K4)

Giada Minelli

Oral presentation

3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities

13:20 to 14:50

Knowledge market 4 (K4)

Nicola Singleton

Oral presentation

4. Estimating the size of the of illicit drug market – a critical review

13:20 to 14:50

Knowledge market 4 (K4)

Robin Udrisard

Oral presentation

1. Overdose prevention and treatment implications of fentanyl use in the United States

13:20 to 14:50

Central square 4 (C4)

Alexander Walley

Oral presentation

2. Digital Health Interventions: Petiscos from clinical practice

13:20 to 14:50

Central square 2 (C2)

Roya Vaziri

Oral presentation

2. Fentanyl related deaths and fentanyl acute toxicity presentations at emergency Departments in Europe, 2010-2020

13:20 to 14:50

Central square 4 (C4)

Peter Heudtlass

Oral presentation

3. High drug-related death mortality in Finland – special focus on young adults and teenagers

13:20 to 14:50

Central square 4 (C4)

Prikko Kriikku

Oral presentation

4. Intentional overdoses and associated mental health challenges, an overlooked sub-population of overdoses

13:20 to 14:50

Central square 4 (C4)

Thomas Clausen

15:00

Oral presentation

5. Changing drug market requires new priorities for Moldova’s law enforcement authorities

2. Lebanon: responding to drug market changes in crisis situation

4. Key developments in drug markets of Eastern European Neighbourhood Policy (ENP) countries

1. Key developments in drug markets of North Africa and Middle East

3. Key developments in drug markets of Western Balkans

15:00 to 16:30

Insights zone 4 (I4)

Robert Patrancus, Katerina Skarupova

Oral presentation

Temporal changes in alcohol consumption associated with the COVID-19 interventions in Belgium: a wastewater-based approach

15:00 to 16:30

Central square 1 (C1)

Maarten Quireyns

Oral presentation

Impacts of changes in alcohol consumption patterns during the first 2020 COVID-19 restrictions for people with and without mental health and neurodevelopmental conditions: A cross sectional study in 13 countries

15:00 to 16:30

Central square 1 (C1)

Gail Gilchrist

Oral presentation

Severe COVID-19 cases among patients admitted to treatment for alcohol and drug use disorders in Catalonia

15:00 to 16:30

Central square 1 (C1)

Jorge Palacio-Vieira

Oral presentation

Disentangling the 'COVID-19 alcohol paradox': reasons for changes in alcohol-specific disease burden during the COVID-19 pandemic in Germany

15:00 to 16:30

Central square 1 (C1)

Jakob Manthey

Oral presentation

1. What do we mean by psychiatric comorbidity or dual disorders?

15:00 to 16:30

Knowledge market 2 (K2)

Marta Torrens

Oral presentation

2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study

15:00 to 16:30

Knowledge market 2 (K2)

Franca Beccaria

Oral presentation

3. Psychiatric comorbidity in the European countries: prevalence and models of care

15:00 to 16:30

Knowledge market 2 (K2)

Francina Fonseca

Oral presentation

4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio

15:00 to 16:30

Knowledge market 2 (K2)

Nusa Segrec, Andrej Kastelic

Oral presentation

Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.

15:00 to 16:30

Knowledge market 3 (K3)

Magdalena Harris

Oral presentation

Analysis of drugs in used syringes from sentinel European cities, 2020

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Seyler

Oral presentation

The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study

15:00 to 16:30

Knowledge market 3 (K3)

Samantha Colledge-Frisby

Oral presentation

1. Quality Assurance Tools: Improving Coverage, Accessibility and Quality of Drug Use Disorder Treatment

15:00 to 16:30

Knowledge market 1 (K1)

Anja Busse

Oral presentation

4. Key factors for a successful implementation of Quality Standards in Drug Demand Reduction – a Delphi Study

15:00 to 16:30

Knowledge market 1 (K1)

Rafaela Rigoni

Oral presentation

2. Further ENhancing the Implementation of Quality Standards in drug demand reduction across Europe (FENIQS-EU) project – study objectives and first realisations

15:00 to 16:30

Knowledge market 1 (K1)

Dijana Jerkovic

Oral presentation

3. State of the Art of Quality Standards implementation in drug demand reduction in Europe

15:00 to 16:30

Knowledge market 1 (K1)

Martina Feric

Oral presentation

5. An inspiring practice example of Quality Standards implementation: the Spanish Good Practice inDemand Reduction Portal (PBBPP)

15:00 to 16:30

Knowledge market 1 (K1)

Alba González-Roz

Oral presentation

1. Convergences in the psychology of behavioral addictions

2. Convergences in the neurobiology of behavioral addictions

3. Convergences in the treatment of behavioral addictions

15:00 to 16:30

Main stage

Susana Jiménez-Murcia, Fernando Fernández-Aranda, Roser Granero

Oral presentation

4. Convergences in behavioral addiction policies

Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project

15:00 to 16:30

Central square 3 (C3)

Ana Araújo

Oral presentation

5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines

15:00 to 16:30

Central square 2 (C2)

Dilkushi Poovendran

Oral presentation

1. Early warning on emerging drug threats at the international level – opportunities and challenges

15:00 to 16:30

Central square 2 (C2)

Martin Raithelhuber

Oral presentation

2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe

15:00 to 16:30

Central square 2 (C2)

Michael Evans-Brown

Oral presentation

3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety

15:00 to 16:30

Central square 2 (C2)

Luli R. Akinfiresoye, Terrence L. Boos

Oral presentation

4. NPS Discovery: An Open Access Early Warning System for the United States

15:00 to 16:30

Central square 2 (C2)

Barry K. Logan

Oral presentation

Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.

15:00 to 16:30

Central square 3 (C3)

Tisdale Calvert

Oral presentation

It is logically not possible to quantify the number of indirect deaths

15:00 to 16:30

Central square 3 (C3)

Alfred Uhl

Oral presentation

Mortality and Morbidity in Patients in Opioid Maintenance Treatment

15:00 to 16:30

Central square 3 (C3)

Roman Gabrhelík

Oral presentation

Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.

15:00 to 16:30

Central square 3 (C3)

Charlotte Buckley

Oral presentation

1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia

2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency

3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs

15:00 to 16:30

Insights zone 3 (I3)

Michael Lodberg Olsen

Oral presentation

4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021

The International Society of Substance Use Professionals (ISSUP)

15:00 to 16:30

Insights zone 2 (I2)

Joanna Travis-Roberts

Oral presentation

How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)

15:00 to 16:30

Knowledge market 4 (K4)

Nadine Hendrie

Oral presentation

Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise

15:00 to 16:30

Knowledge market 4 (K4)

Vivian Hope

Oral presentation

Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study

15:00 to 16:30

Knowledge market 4 (K4)

Gary Chan

Oral presentation

Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers

15:00 to 16:30

Knowledge market 4 (K4)

Kyla Thomas

Oral presentation

Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study

15:00 to 16:30

Knowledge market 4 (K4)

Jason Grebely

Oral presentation

PLATO, an e-learning platform for European learners

European initiatives on training: a cumulative experience

UNODC- prevention quality standards

Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Brothers

Oral presentation

0. Convergence in behavioural addictions: Introduction

3 Scenarios, 3 Alternative Addiction Futures for 2040

15:00 to 16:30

Central square 4 (C4)

Jessica Prendergast

Oral presentation

Does university education and training on addictions really represent new opportunity for increasing quality of workforce and addiction specific services in prevention, treatment and harm reduction?

16:50

1. Analysis of NPS and drugs purchased on Darknet and Clearnet markets

2. The influence of legislation on the availability of NPS

3. Prevalence of NPS use. Results of the implementation of a standardized survey methodology amongst 25 civil society organization in Europe

1. The Impact of Economic Recessions on the Use of Illicit Drugs: a Systematic Review of Literature and a Meta-Analysis

16:50 to 18:20

Central square 4 (C4)

Claudia Costa Storti

Oral presentation

2. The impact of economic recessions on the harms of drug use and health responses, in Europe: a panel data analysis

16:50 to 18:20

Central square 4 (C4)

Bruno Casal

Oral presentation

3. Structural vulnerabilities and deaths of despair in Scotland, 1980-2021

16:50 to 18:20

Central square 4 (C4)

Mirjam Allik

Oral presentation

Integrating the Notions of Complexity and Social Suffering to Provide Better Care to Sexually and Gender-Diverse Men Who Use Methamphetamine

Sustaining non-use of party drugs among Dutch young adults

Why do young people use cannabis – or decide not to?

16:50 to 18:20

Insights zone 2 (I2)

Anne Line Bretteville-Jensen

Oral presentation

LEt’s Talk about drugs: Assessment of drug education in Bulgaria, Hungary, Lithuania, Poland, and Serbia

Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study

16:50 to 18:20

Central square 1 (C1)

Bram Pussig

Oral presentation

Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States

16:50 to 18:20

Central square 1 (C1)

Carolina Barbosa

Oral presentation

Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries

16:50 to 18:20

Central square 1 (C1)

Gregor Zwirn

Oral presentation

The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals

16:50 to 18:20

Central square 1 (C1)

Sergio Flores

Oral presentation

Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety

16:50 to 18:20

Central square 1 (C1)

Beau Kilmer

Oral presentation

4. Illegal substance use during pregnancy: what do we know about risks and detoxification?

16:50 to 18:20

Central square 2 (C2)

Cleo L. Crunelle

Oral presentation

2. Impact and lessons learned in the implementation of a NBP model across the province of Quebec, Canada

16:50 to 18:20

Knowledge market 2 (K2)

Joël Tremblay

Oral presentation

1. Implementation of a substance use NBP model in a Northern Region of Ontario- results and lessons learned

16:50 to 18:20

Knowledge market 2 (K2)

Stephanie Paquette

Oral presentation

3. Development and pilot testing an integrated mental health and substance use Needs-based Planning model: Lessons learned for local planning and model refinements

16:50 to 18:20

Knowledge market 2 (K2)

Brian Rush

Oral presentation

1. First findings of an RCT on treatment of PTSD in addiction: simultaneous or sequential treatment with EMDR, Prolonged Exposure, Imaginary Rescripting

16:50 to 18:20

Central square 2 (C2)

Nathalie Faber

Oral presentation

5. Focus on implementation processes, impacts to date and pros and cons of the sustainability of the Australian Mental Health model

16:50 to 18:20

Knowledge market 2 (K2)

Sandra Diminic

Oral presentation

2. Older adults and alcohol use: negative affect, resilience, and alcohol use as interacting factors

16:50 to 18:20

Central square 2 (C2)

Yannick van Gils

Oral presentation

3. Effectiveness of a digital alcohol moderation intervention as an add-on to depression treatment for young adults: findings of a pragmatic randomized controlled trial

16:50 to 18:20

Central square 2 (C2)

Maria J.E. Schouten

Oral presentation

1. International Guidelines on Human Rights and Drug Policy: From standard setting to assessing compliance

16:50 to 18:20

Knowledge market 1 (K1)

Damon Barrett

Oral presentation

2. Pompidou Group for Human rights and drug policies in Europe: A self-assessment tool

16:50 to 18:20

Knowledge market 1 (K1)

Thomas Kattau

Oral presentation

3. The Global Drug Policy Index: A unique accountability tool to assess and rank countries’ drug policies

16:50 to 18:20

Knowledge market 1 (K1)

Juan Fernandez Ochoa

Oral presentation

1. The standard THC unit

2. Paving the Way for Improved Data Collection on Cannabis Use

3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits

4. From standard drinks to the cannabis toolkit

1. Experimental studies on cannabis and driving impairment

2. Epidemiological studies on cannabis and crash risk

3. Toxicology: detection of THC impairment

4. Policy and legislation

An international rapid review of the needs and an indirect estimate of the national prevalence of women who use substances and endure domestic violence.

16:50 to 18:20

Central square 3 (C3)

Catherine Comiskey

Oral presentation

5. Medical use and novel cannabinoids

What are the attitudes of pregnant women and mothers concerning maternal alcohol use, and what factors are associated with increased maternal drinking?

16:50 to 18:20

Central square 3 (C3)

Abi Rose

Oral presentation

Identifying the needs of mothers in substance use treatment services using electronic health records

16:50 to 18:20

Central square 3 (C3)

Martha Canfield

Oral presentation

Metzineres. Environments of Shelter for Womxn who use drugs surviving violence

16:50 to 18:20

Central square 3 (C3)

Aura Roig Forteza

Oral presentation

Prevalence of Tobacco Smoking in Austria. Differences between Women and Men

16:50 to 18:20

Central square 3 (C3)

Irene Schmutterer

Oral presentation

1. The role of social work in agency processes - empirical study using the example of people who use illicit substances with a history of imprisonment

16:50 to 18:20

Networking zone 1 (N1)

Daniela Jamin

Oral presentation

2. Social work with drug users in a probation system of Kyrgyzstan

16:50 to 18:20

Networking zone 1 (N1)

Estebes uulu Tynchtyk

Oral presentation

3. Health and social welfare in prisons in the Republic of Kazakhstan – women with HIV and the role of the social worker

16:50 to 18:20

Networking zone 1 (N1)

Dalida Mukasheva

Oral presentation

Drug treatment facilities survey, Tunisia 2020

16:50 to 18:20

Networking zone 2 (N2)

Hajer Aounallah-Skhiri

Oral presentation

Findings from treatment facility survey (EFSQ) in Lebanon’

16:50 to 18:20

Networking zone 2 (N2)

Zeinab Abbas

Oral presentation

European facility survey questioner (EFSQ) for Palestinian substance use disorder (SUD) treatment facilities.

16:50 to 18:20

Networking zone 2 (N2)

Saed Bilbeisi

Oral presentation

European treatment facility survey in Georgia

16:50 to 18:20

Networking zone 2 (N2)

Irakli Natsvlishvili

Oral presentation

1. Interventions to enhance prevention of hepatitis C and HIV infection

16:50 to 18:20

Knowledge market 3 (K3)

Julie Bruneau

Oral presentation

2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle

16:50 to 18:20

Knowledge market 3 (K3)

Matthew Hickman

Oral presentation

3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?

16:50 to 18:20

Knowledge market 3 (K3)

Jason Grebely

Oral presentation

4. Community-led initiatives to enhance prevention and treatment for hepatitis C

16:50 to 18:20

Knowledge market 3 (K3)

Judy Chang

Thursday, 24 November

09:00

Oral presentation

2. Addiction Curriculum in Nigerian Higher Education System – Contextualizing Western-based methods and approaches for responsiveness and effectiveness.

09:00 to 10:30

Central square 4 (C4)

Martin Agwogie

Oral presentation

3. Piloting an implementation protocol delivered as an online course: African leadership in addiction workforce development

09:00 to 10:30

Central square 4 (C4)

Beatrice Kathungu

Oral presentation

1. Needs Assessment of Addiction Science Programmes at Universities in South Africa and Preparatory work for curriculum development

09:00 to 10:30

Central square 4 (C4)

Rehana Kader

Oral presentation

2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend

09:00 to 10:30

Knowledge market 4 (K4)

José Benito Quintana

Oral presentation

3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings

09:00 to 10:30

Knowledge market 4 (K4)

Victor Villanueva

Oral presentation

4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework

09:00 to 10:30

Knowledge market 4 (K4)

Fernando Rodriguez De Fonseca

Oral presentation

1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services

09:00 to 10:30

Knowledge market 4 (K4)

Joan-Ignasi Mestre-Pintó

Oral presentation

ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia

09:00 to 10:30

Central square 2 (C2)

Fred Cameron

Oral presentation

Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field

09:00 to 10:30

Central square 2 (C2)

Tuulia Lerkkanen

Oral presentation

Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission

09:00 to 10:30

Central square 2 (C2)

Zoe Ward

Oral presentation

Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme

09:00 to 10:30

Central square 2 (C2)

Gail Gilchrist

10:50

Oral presentation

2. HTP prevalence in England and use for smoking cessation

3. Perceived health risks of heated tobacco products, tobacco cigarettes, and e-cigarettes: Findings from a populationbased cross-sectional household survey in Germany (DEBRA study)

10:50 to 12:20

Insights zone 4 (I4)

Stephanie Klosterhalfen

Oral presentation

4. Harm perceptions of heated tobacco products and vaping among students at Lithuanian universities

5. It’s not what you’d term normal smoking’: A qualitative exploration of HTP user identity

1. Global Prevalence of Heated Tobacco Product Use: A Systematic Review and Meta-analysis

Non-drinking as deviant! First attempts to use the Relational Responding Task to alter drinking identity in an experimental study.

The Power of Social Networks: Trial Outcomes of a Two-Stage Social Network Intervention Aimed at Reducing Hazardous Drinking in the First Twelve Months at Residential College.

The association between social media use and substance use behaviour among adolescents: The ABCD-Study

Quem conta um conto acrescenta um ponto': Drugs as news in Portugal

Implementing a Moderate Alcohol Use Program for Indigenous People: A Stakeholder Perspective

10:50 to 12:20

Central square 1 (C1)

Pascale Alarie-vézina

Oral presentation

Simulation of Alcohol Control Policies for Health Equity (SIMAH): Study design and first results

10:50 to 12:20

Central square 1 (C1)

Charlotte Probst, Robin Purshouse

Oral presentation

Noticed and then forgotten: gender in alcohol policy stakeholder responses to alcohol and violence

10:50 to 12:20

Central square 1 (C1)

David Moore

Oral presentation

Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European Region: a modelling study

10:50 to 12:20

Central square 1 (C1)

Pol Rovira Escarrà

Oral presentation

The association between moral injury and cannabis use disorder among Israeli combat veterans: current state of knowledge and future directions

10:50 to 12:20

Knowledge market 2 (K2)

Daniel Feingold

Oral presentation

Alcohol and drug use among trauma patients with injuries of violence– results from the IDART study

10:50 to 12:20

Knowledge market 2 (K2)

Benedicte Jørgenrud

Oral presentation

addictive disorders and post-traumatic stress disorders

10:50 to 12:20

Knowledge market 2 (K2)

Léa Montagnier

Oral presentation

A novel trauma-focused psychological therapy for co-occurring substance use and PTSD among adolescents

10:50 to 12:20

Knowledge market 2 (K2)

Emma Barrett

Oral presentation

Experienced gratification and compensation in addictive behaviors: Investigating its relevance in different types of Internet-use disorders

Understanding first controlled gaming in teenagers. A qualitative study among young French daily or week-end gamers

Assessment of Criteria for Specific Internet-use Disorders (ACSID-11):Further development and validation of a new screening instrument capturing ICD-11 criteria for gaming disorder and other potential Internet-use disorders

Problematic gaming risk among European adolescents: A cross-national evaluation of individual and socio-economic factors

Effects of COVID-19 lockdowns on addiction to social networking sites and associations with changes in loneliness, sexual functioning, and eating styles

1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization

10:50 to 12:20

Knowledge market 1 (K1)

David Hammond

Oral presentation

2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

Cesar Leos-Toro

Oral presentation

3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study

10:50 to 12:20

Knowledge market 1 (K1)

TBD TBD

Oral presentation

Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway

10:50 to 12:20

Knowledge market 3 (K3)

John Todd-kvam

Oral presentation

Integrating harm reduction in homelessness services. The HR4H Key Principles

10:50 to 12:20

Knowledge market 3 (K3)

Roberto Perez Gayo

Oral presentation

1. Synthetic opioids in Sweden: Analyses of public webforum discussions

10:50 to 12:20

Central square 2 (C2)

Kim Moeller

Oral presentation

2. From the jungle to the street: Country-level variation and demographic correlates of cocaine prices

10:50 to 12:20

Central square 2 (C2)

Rasmus Munksgaard

Oral presentation

3. Illegal drug markets on social media: Locally bound actors on global platforms

10:50 to 12:20

Central square 2 (C2)

Silje Anderdal Bakken

Oral presentation

4. How do you become involved in hybrid digital drug markets: Identifying explanations in a qualitative interview study with social media sellers

10:50 to 12:20

Central square 2 (C2)

Jakob Demant

Oral presentation

Mental health and associations with tobacco smoking and quitting behaviour in the population of Germany

10:50 to 12:20

Central square 3 (C3)

Sabrina Kastaun

Oral presentation

Neuropsychology of Addictions in Therapeutic Communities: assessing and understanding cognitive recovery through a residential treatment of substance use disorders

10:50 to 12:20

Central square 3 (C3)

Simon Deniel

Oral presentation

Administration matters! A retrospective cohort study of medication dispensing at pharmacies

10:50 to 12:20

Knowledge market 3 (K3)

Birgitte Thylstrup

Oral presentation

Binge alcohol intake triggers microglial activation and TNF-dependent aberrant synaptic pruning, causing synapse loss and increased anxiety

10:50 to 12:20

Central square 3 (C3)

Teresa Summavielle

Oral presentation

Primary Care Provider expectations of addiction services and patients in Spain.

10:50 to 12:20

Knowledge market 3 (K3)

Pablo Barrio

Oral presentation

High dose anabolic steroid use and facial emotion recognition, the hormonal influence on social cognition.

10:50 to 12:20

Central square 3 (C3)

Astrid Bjørnebekk

Oral presentation

Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.

10:50 to 12:20

Knowledge market 3 (K3)

Jennifer Scott

Oral presentation

2. Streetwork and Outreach Networking

10:50 to 12:20

Knowledge market 4 (K4)

Lagakou Litsa

Oral presentation

3. Direct access to OST treatment and integrated therapy: Lessons learned from streets to community

10:50 to 12:20

Knowledge market 4 (K4)

Nikos Avgerinos

Oral presentation

4. Harm Reduction and Covid 19: Hostel 'IONIS', an example of a holistic intervention for homeless drug users

10:50 to 12:20

Knowledge market 4 (K4)

Foteini Leobilla

Oral presentation

1. The 4 pillar drug policy and city overview

10:50 to 12:20

Central square 4 (C4)

Andrea Weiss

Oral presentation

3. t-alk' and 'City' – low-threshold meeting places for a diverse clientele

10:50 to 12:20

Central square 4 (C4)

Larissa Stämpfli

Oral presentation

2. Surpervised drug consumption facilities (SDCF)

10:50 to 12:20

Central square 4 (C4)

Janine Lanz

Oral presentation

4. sip züri' - entry control of safe injection facilities, and from social space management to social ambulance

10:50 to 12:20

Central square 4 (C4)

Mara Brügger

Oral presentation

5. Flora Dora' and prostitution area team: outreach social work for sexworkers and low-threshold counselling on the spot

10:50 to 12:20

Central square 4 (C4)

Ursula Kocher

Oral presentation

1. Steps forward in an attempt of OKANA to widen harm reduction to risk reduction: entries and facilities within a new concept based on the real needs

10:50 to 12:20

Knowledge market 4 (K4)

Athanasios Theocharis

Oral presentation

1. Representations of narcoculture

10:50 to 12:20

Insights zone 1 (I1)

América Tonantzin Becerra Romero

Oral presentation

2. Journalism and illegal drugs, a complex relationship

3. Harm reduction and addiction in social media. How to do it right?

4. ACEs to Assets

12:20

Health and social effects of non-medical cannabis use: an update

12:40

What is new in the WHO Consolidated Guidelines for HIV, viral hepatitis and STI prevention, diagnosis and treatment for key populations

12:50

Global monitoring of progress with attainment of SDG health target 3.5 and service capacity for substance use disorders

13:20

Codesigning an Australian National Prompt Response Network for Emerging Drugs

A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of Eastern Europe and Central Asia region

In vitro pharmacological characterization of recent non-fentanyl synthetic opioids including 2-benzylbenzimidazole ‘nitazene’ opioids

Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services

3. Municipalities in the lead: an approach to tackle GHB-related problems in the Netherlands.

1. Development and implementation of an environmental prevention intervention at local level

2. Choosing our theories wisely: the importance of theory for effective and ethical environmental prevention

Drinking with Coworkers – How to Make it a Safe and Including Event

13:20 to 14:50

Central square 1 (C1)

Stian Fjerdingen

Oral presentation

Accuracy, acceptability, and feasibility of transdermal alcohol sensors: Two systematic reviews

13:20 to 14:50

Central square 1 (C1)

Eileen Brobbin

Oral presentation

Perceived barriers and facilitators to accessing effective clinical supervision and the implementation of a clinical supervision exchange model in the alcohol and other drug sector

13:20 to 14:50

Central square 1 (C1)

Courtney O'Donnell

Oral presentation

Using technology to digitally disrupt the delivery of outcome measures in Alcohol and Other Drug (AOD) services

13:20 to 14:50

Central square 1 (C1)

Leanne Hides

Oral presentation

The Role of Adverse Childhood Experiences (ACEs) on People in Opiate Agonist Treatment: The importance of feeling unloved

13:20 to 14:50

Knowledge market 2 (K2)

David McDonagh

Oral presentation

Longitudinal patterns of problematic cannabis use in adolescence and their association with childhood psychological risk factors

13:20 to 14:50

Knowledge market 2 (K2)

Rachel Lees

Oral presentation

Childhood maltreatment and alcohol problems in young adulthood: coping style as a mediator and potential intervention target.

13:20 to 14:50

Knowledge market 2 (K2)

Lucinda Grummitt

Oral presentation

Exploring the link between childhood maltreatment and substance use disorder using a prospective, genetically informative and experimental approach

13:20 to 14:50

Knowledge market 2 (K2)

Andrea Johansson Capusan

Oral presentation

Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study

13:20 to 14:50

Knowledge market 3 (K3)

Anna Conway

Oral presentation

Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis

13:20 to 14:50

Knowledge market 3 (K3)

Suzanne Fraser

Oral presentation

A novel hepatitis C intervention in Denmark to test and treat people who inject drugs

13:20 to 14:50

Knowledge market 3 (K3)

Jonas Demant

Oral presentation

Gambling addiction, gambling related harm and gambling problems - a knowledge synthesis and research agenda

Competing framings of gambling as a distinct vs similar problem – boundary making with substance use and eating disorders.

Putting together the puzzle of gambling addiction

1. Cannabis Social Clubs in Europe: a transnational social movement network in the making?

13:20 to 14:50

Knowledge market 4 (K4)

Melissa Bone

Oral presentation

3. Legal or not: a comparative analysis of Belgian and Uruguayan CSC members’ profile and policy preferences

13:20 to 14:50

Knowledge market 4 (K4)

Lorena Repetto

Oral presentation

4. Drug social clubs – the next social club generation?

13:20 to 14:50

Knowledge market 4 (K4)

Chris Wilkins

Oral presentation

2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach

13:20 to 14:50

Central square 2 (C2)

Hayley E. Jones

Oral presentation

3. Estimates of people who injected drugs within the past 12 months in France

13:20 to 14:50

Central square 2 (C2)

Eric Janssen

Oral presentation

4. How many people injected illicit drugs in the European Union in 2019?

13:20 to 14:50

Central square 2 (C2)

Filippo Pericoli

Oral presentation

1. Estimates of people who injected drugs within the last 12 months in Belgium

13:20 to 14:50

Central square 2 (C2)

Luk Van Baelen

Oral presentation

5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021

13:20 to 14:50

Central square 2 (C2)

Samantha Colledge-Frisby

Oral presentation

What will the future nicotine market look like in a post-smoking era?

13:20 to 14:50

Central square 3 (C3)

Karl Erik Lund

Oral presentation

Effectiveness of e-cigarettes for smoking cessation in the German population - a comparison with nicotine replacement therapy and no use of evidence-based support (DEBRA study)

13:20 to 14:50

Central square 3 (C3)

Daniel Kotz

Oral presentation

The lifetime costs and benefits of subsidizing the cost of nicotine replacement therapy in Sweden

13:20 to 14:50

Central square 3 (C3)

Inna Feldman

Oral presentation

Cessation of Smoking Trial in the Emergency Department- interim results

13:20 to 14:50

Central square 3 (C3)

Ian Pope

Oral presentation

Motivation to stop smoking in the German population: recent trends and associated factors (DEBRA study)

13:20 to 14:50

Central square 3 (C3)

Benjamin Borchardt

Oral presentation

1. Association of cannabis and tobacco use with incident anxiety, mood and psychotic disorders: a systematic review

13:20 to 14:50

Knowledge market 1 (K1)

Chloe Burke

Oral presentation

3. The Cannabis And Tobacco Cessation Advice (CATCA) project: A mixed method study exploring UK stop smoking practitioners’ knowledge, attitudes and practices around co-use

13:20 to 14:50

Knowledge market 1 (K1)

Maria Duaso

Oral presentation

4. Changes in tobacco use among people with cannabis use disorder treated in programs

13:20 to 14:50

Knowledge market 1 (K1)

Cristina Martínez

Oral presentation

2. Quitting experiences, attitudes and beliefs amongst UK young adult co-smokers: A qualitative interview study

13:20 to 14:50

Knowledge market 1 (K1)

Hannah Walsh

Oral presentation

4. A qualitative exploration of three hypothetical models of drug checking service delivery in a Scottish context

13:20 to 14:50

Central square 4 (C4)

Danilo Falzon

Oral presentation

The added value of drug checking data in combination with data from online drug monitoring to evaluate NPS market dynamics: the case of 3-MMC in the Netherlands.

1. Implementing community-based drug checking services in two Canadian provinces: lessons learned and ways forward

13:20 to 14:50

Central square 4 (C4)

Karen McDonald

Oral presentation

2. Tailoring drug checking services to Drug Consumption Rooms

13:20 to 14:50

Central square 4 (C4)

Mireia Ventura

Oral presentation

3. Drug checking in DCRs in Switzerland: a new harm reduction tool?

13:20 to 14:50

Central square 4 (C4)

Florian Meyer, Pierre Esseiva

Oral presentation

1. How Robust and Innovative are Illegal Drug Markets?

2. To what extent can drug violence indicators tell us something about underlying drug market activity?

2. What are the barriers and prospects for establishing Cannabis Social Clubs in New Zealand?

13:20 to 14:50

Knowledge market 4 (K4)

Marta Rychert

Oral presentation

4. The geography of drug markets and hotspots of violence

15:00

5. Modeling safer supply programs: a qualitative evaluation of three safer opioid supply program models in British Columbia, Canada

15:00 to 16:30

Insights zone 4 (I4)

Andrew Ivsins, Geoff Bardwell

Oral presentation

2. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021

1. Why people who use drugs need a safe regulated supply of all drugs

15:00 to 16:30

Insights zone 4 (I4)

Natasha Touesnard, Matthew Alexander Bonn

Oral presentation

3. A mixed methods evaluation of risk mitigation measures to address the dual public health crisis of COVID-19 and overdose

15:00 to 16:30

Insights zone 4 (I4)

Karen Urbanoski, Bernie Pauly

Oral presentation

Quality management in prevention of risk behaviors in school setting: a Case study from Czech republic

4. A sea of need – Safe opioid supply service provider accounts of implementing admission priorities

The 7-year effectiveness of school-based alcohol use prevention from adolescence to early adulthood: An RCT of universal, selective and combined interventions.

Design and Evaluation of a neuroscience-based, harm reduction program to prevent alcohol and illicit substance use among late adolescents: An RCT of the Illicit Project

Durability of anxiety, depression, and substance use prevention effects from teenage years to young adulthood: 6-year outcomes from a school-based cluster randomised controlled trial delivered in adolescence.

2. Lessons for the future of alcohol surveys

15:00 to 16:30

Central square 1 (C1)

Jürgen Rehm

Oral presentation

1. Developing and Extending Evidence and Practice from the Standard European Alcohol Survey (DEEP SEAS): Key findings, strengths, and limitations

15:00 to 16:30

Central square 1 (C1)

Carolin Kilian

Oral presentation

The role of place-making dynamics in recovery from co-occurring disorders: An in-depth ethnographic study

15:00 to 16:30

Knowledge market 2 (K2)

Clara De Ruysscher

Oral presentation

The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study

15:00 to 16:30

Knowledge market 3 (K3)

Kari Lancaster

Oral presentation

Changes in mental health among drug users during Covid-19. Evidence from a repeated cross-sectional survey in Belgium

15:00 to 16:30

Knowledge market 2 (K2)

Elena Damian

Oral presentation

Online peer support for concurring mental health and addiction problems during the Covid19 pandemic: feeling of group inclusion and perceived effectiveness.

15:00 to 16:30

Knowledge market 2 (K2)

Raffaella Milani

Oral presentation

2. Where does the gambling surplus come from? Outline of a theory of asymmetric market

3. The framing of commercial determinants of harm: challenges for regulation in the UK

15:00 to 16:30

Insights zone 3 (I3)

Heather Wardle, Gerda Reith

Oral presentation

4. Meta-analysis of self-regulation discourses

5. Ways gambling industry pursues influence with policymakers

1. State-owned gambling in global competitive environment

15:00 to 16:30

Insights zone 3 (I3)

Johanna Järvinen-Tassopoulos

Oral presentation

Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.

15:00 to 16:30

Knowledge market 3 (K3)

Jan Gryczynski

Oral presentation

Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon

15:00 to 16:30

Knowledge market 3 (K3)

Filipa Barata

Oral presentation

Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK

15:00 to 16:30

Knowledge market 3 (K3)

Julian Surey

Oral presentation

2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice

15:00 to 16:30

Knowledge market 1 (K1)

Karen Duke

Oral presentation

3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives

15:00 to 16:30

Knowledge market 1 (K1)

Katie Colliver

Oral presentation

4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives

15:00 to 16:30

Knowledge market 1 (K1)

Betsy Thom

Oral presentation

5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality

15:00 to 16:30

Knowledge market 1 (K1)

Brian Kelly

Oral presentation

1. Drug-related deaths among young people: a social, structural and systems autopsy

15:00 to 16:30

Knowledge market 1 (K1)

Aileen O'Gorman

Oral presentation

2. Improving the self: Psychedelic drug use and the enhancement-treatment debate

3. Psychedelics in psychiatry: focus on evidence and mechanisms of relevance to affective disorders and addictions

1. Combining Psychedelic Treatments with Current Substance Use Disorder Treatments

2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs

15:00 to 16:30

Central square 2 (C2)

Eva-Carina Heier

Oral presentation

3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset

15:00 to 16:30

Central square 2 (C2)

Òscar Miró

Oral presentation

4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020

15:00 to 16:30

Central square 2 (C2)

Isabelle Giraudon

Oral presentation

Who is using take-home naloxone? An examination of super-savers

15:00 to 16:30

Central square 3 (C3)

Desiree Eide

Oral presentation

Examining health care from the drug user perspective: what works, what doesn't and what needs to change

15:00 to 16:30

Central square 3 (C3)

Mary Ellen Harrod

Oral presentation

An Evaluation of the Co-Design of an Anti-Stigma Training Programme

15:00 to 16:30

Central square 3 (C3)

Sonam Prakashini Banka

Oral presentation

Once you’ve addressed your drinking, we’ll address your mental health': A qualitative exploration of patient and providers’ experiences of services for co-occurring heavy drinking and depression in North East England

15:00 to 16:30

Central square 3 (C3)

Amy O'Donnell

Oral presentation

Police officers’ attitudes and practices toward harm reduction services in Sweden – a qualitative study

15:00 to 16:30

Central square 3 (C3)

Johan Nordgren

Oral presentation

1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network

15:00 to 16:30

Central square 2 (C2)

Benjamin Crulli

Oral presentation

3. Development of tailored prevention intervention packages

15:00 to 16:30

Knowledge market 4 (K4)

Magdalena Rowicka

Oral presentation

1. Aims, scope and methodology of IMPRESA

15:00 to 16:30

Knowledge market 4 (K4)

Dovilė Mačiulytė

Oral presentation

2. Results of the literature review and the Delphi expert consensus finding process on Methamphetamine Prevention Interventions

15:00 to 16:30

Knowledge market 4 (K4)

Benjamin Petruželka

Oral presentation

4. The RE-AIM framework for evaluating implementation processes and public health impact

15:00 to 16:30

Knowledge market 4 (K4)

Harald Lahusen

Oral presentation

3. Are there good alternatives or add ons to surveys?

15:00 to 16:30

Central square 1 (C1)

Pia Mäkelä

Oral presentation

0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction

15:00 to 16:30

Central square 2 (C2)

Paul Dargan

16:50

Oral presentation

1. Drug Market and Use Changes During the COVID-19 Pandemic: A Global Survey

16:50 to 18:20

Insights zone 4 (I4)

Alexander Baldacchino

Oral presentation

2. Cognitive Training and Rehabilitation Approaches for Addiction: A Delphi Consensus

3. A Methodological Checklist for fMRI Cue Reactivity Studies in Addictions: Development and Expert Consensus

16:50 to 18:20

Insights zone 4 (I4)

Antonio Verdejo-Garcia

Oral presentation

4. Translating Neuroscience into Addiction Prevention: A Delphi Consensus Study

5. Global Experts-centered Consensus Development; A Series of Methodologies for Extending Harmonization and Global Representativeness in Addiction Science

16:50 to 18:20

Insights zone 4 (I4)

Arash Khojasteh Zonoozi

Oral presentation

The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.

16:50 to 18:20

Central square 3 (C3)

Anne Whittaker

Oral presentation

1. A predictive processing account of problem gambling

2. Flow in (problem) gambling

3. The ethical implications of how problem gambling is conceptualized

The limitations of decriminalization at overdose events and lessons from an evaluation in British Columbia, Canada

16:50 to 18:20

Knowledge market 1 (K1)

Alissa Greer

Oral presentation

Medical cannabis regulation: Taking the best of the North American and European models

The change in methadone dispensing requirements in England during the first wave of the COVID-19 pandemic was associated with an increase in deaths from non-prescribed methadone

16:50 to 18:20

Knowledge market 1 (K1)

Caroline Copeland

Oral presentation

Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada

Differences in cannabis use and opinions on drug policy between generations

16:50 to 18:20

Central square 2 (C2)

Pekka Hakkarainen

Oral presentation

Long term public health benefits and cost-effectiveness of two experimental drug consumption rooms in France

16:50 to 18:20

Knowledge market 1 (K1)

Perrine Roux

Oral presentation

Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in

Adolescent cannabis use during a period of rapid policy change: Evidence from the US PATH Study

16:50 to 18:20

Central square 2 (C2)

Mike Vuolo

Oral presentation

The United Kingdom’s first unsanctioned safe injecting facility; a proof-of-concept evaluation

16:50 to 18:20

Knowledge market 1 (K1)

Gillian Shorter

Oral presentation

Regulating Cannabis for Public Health

The role played by evidence on the effects of cannabis use in cannabis policy 1992-2022

16:50 to 18:20

Central square 2 (C2)

Eva Hoch

Oral presentation

First low-threshold gender responsive residential resource for homeless people using drugs in Barcelona: descriptive evaluation of the first 6 months of activity.

16:50 to 18:20

Knowledge market 1 (K1)

Gabriela Barbaglia

Oral presentation

Mitigating the risks of corporate capture in emerging legal cannabis markets

Trajectories of Prescribed Medical Cannabis Filled Over Time

16:50 to 18:20

Central square 2 (C2)

Alexandra Kritikos

Oral presentation

Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.

Suicide and self-harm during COVID-19 and beyond.

Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.

Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.

3. Brain reward function in young people with a dsm-5 diagnosis of Cannabis Use Disorder: a fMRI study

16:50 to 18:20

Knowledge market 2 (K2)

Valentina Lorenzetti

Oral presentation

1. Cannabis use disorder and the brain: What’s culture got to do with it?

16:50 to 18:20

Knowledge market 2 (K2)

Janna Cousijn

Oral presentation

2. Resting state functional connectivity of the dorsal attention network in cannabis use disorder: a fMRI study

16:50 to 18:20

Knowledge market 2 (K2)

Lisa-Marie Greenwood

Oral presentation

Identification of cannabis user profiles and their engagement with polydrug use among respondents of the European Web Survey on Drugs: findings from Luxembourg

16:50 to 18:20

Knowledge market 3 (K3)

Tom Kugener

Oral presentation

4. Neural response to reward anticipation after acute exposure to cannabis with and without cannabidiol in adults and adolescents

16:50 to 18:20

Knowledge market 2 (K2)

Martine Skumlien

Oral presentation

E-cigarette use and conventional cigarette smoking among high school students in 35 European countries: findings from the 2019 ESPAD survey

16:50 to 18:20

Knowledge market 3 (K3)

Sonia Cerrai

Oral presentation

5. Acute effects of four CBD:THC ratios on attentional bias to cannabis and food cues: a randomized, double-blind, crossover study

16:50 to 18:20

Knowledge market 2 (K2)

Dominic Oliver

Oral presentation

Laughing gas (N2O) in The Netherlands: where a quick rise in use required action

16:50 to 18:20

Knowledge market 3 (K3)

Desiree Spronk

Oral presentation

Identifying subgroups of Dutch cannabis users based on help-seeking preferences: a latent class analysis

16:50 to 18:20

Knowledge market 3 (K3)

Marleen Olthof

Oral presentation

A National Recovery Study in Higher Education Institutions in Ireland

16:50 to 18:20

Knowledge market 3 (K3)

Ivers Jo-Hanna

Oral presentation

2. Motivational Interviewing for CUD: current situation and gaps

16:50 to 18:20

Knowledge market 4 (K4)

Hugo López Pelayo

Oral presentation

3. Cultural and language adaptation to Spanish of CANnabis DISorder Program (CANDIS)

16:50 to 18:20

Knowledge market 4 (K4)

Pablo Guzmán

Oral presentation

4. Pros and Cons of Group Therapy for Cannabis Use Disorders: Is it an opportunity for cultural adaptation?

16:50 to 18:20

Knowledge market 4 (K4)

Mercè Balcells

Oral presentation

Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study

16:50 to 18:20

Central square 3 (C3)

Olivia Marcus

Oral presentation

EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)

16:50 to 18:20

Central square 3 (C3)

John Marsden

Oral presentation

1. Assisting drug policies in the quest for an evidence-base: challenges related to the development of a National Action Plan for the Drug Information System

16:50 to 18:20

Networking zone 2 (N2)

Viktor Mravcik

Oral presentation

Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.

16:50 to 18:20

Central square 3 (C3)

Cathy Kelleher

Oral presentation

2. Shared responsibilities among different stakeholders in the quest for evidence: experiences from Georgia

16:50 to 18:20

Networking zone 2 (N2)

Ketevan Sarajishvili

Oral presentation

6. European Prevention Curriculum – a tool for disseminating effective modern prevention approaches and facilitating well-informed choices about funding and implementation priorities: reflections from Georgia

16:50 to 18:20

Networking zone 2 (N2)

Jana D. Javakhishvili

Oral presentation

3. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs

16:50 to 18:20

Networking zone 2 (N2)

Anna Tarján

Oral presentation

4. Capacity building for practitioners on evidence-based drug treatment interventions aligned with EU quality standards and tailored to national needs: reflections from Georgia

16:50 to 18:20

Networking zone 2 (N2)

David Otiashvili

Oral presentation

5. The importance of an evidence-based approach in the development of a national drug policy

16:50 to 18:20

Networking zone 2 (N2)

Artur Malczewski

Oral presentation

1. Pharmacological treatments for cannabis use disorder

16:50 to 18:20

Knowledge market 4 (K4)

Albert Batalla

Oral presentation

2. Characteristics associated with drug use during the current detention – results from prison surveys in 4 EU countriessurveys in 4 EU countries

16:50 to 18:20

Central square 1 (C1)

Els Plettinckx

Oral presentation

5. Social determinants, health service contacts and incarceration among all those dying from an accidental overdose 2010-2018 in Norway

16:50 to 18:20

Central square 1 (C1)

Ellen J. Amundsen

Oral presentation

3. Reimprisonment rates among men who inject drugs in Victoria, Australia

16:50 to 18:20

Central square 1 (C1)

Ashleigh C. Stewart

Oral presentation

4. Adverse childhood experiences, substance use, and involvement with correctional services

16:50 to 18:20

Central square 1 (C1)

Richard Pates

Oral presentation

6. Wasted': the complex trajectories from incarceration to recovery. A personal experience

16:50 to 18:20

Central square 1 (C1)

Mark Johnson Ferguson

Oral presentation

1. Use pathways in prison. A French literature review

16:50 to 18:20

Central square 1 (C1)

Caroline Protais

Oral presentation

Signals from the future: Exploring implications for drug policies

16:50 to 18:20

Central square 4 (C4)

Laura Smit-rigter

18:30

Oral presentation

3. HCV treatment uptake among marginalized people who inject drugs in Norway: A registry-based study, and the Progress towards elimination of hepatitis C among people who inject drugs in Norway

18:30 to 19:30

Knowledge market 4 (K4)

Knut Boe Kielland

Oral presentation

2. Opportunistic Treatment of Hepatitis C Virus Infection: A pragmatic stepped-wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs (OPPORTUNI-C)

18:30 to 19:30

Knowledge market 4 (K4)

Olav Dalgard

Oral presentation

1. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program. And new models to reach those hard to reach; results from Point of Care testing and treatment in a nurse led and a peer led mobile clinic

18:30 to 19:30

Knowledge market 4 (K4)

Linda Wüsthoff

Friday, 25 November

09:00

Oral presentation

An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial

09:00 to 10:30

Central square 2 (C2)

Liam Acheson

Oral presentation

Recovery and substitute addictions

09:00 to 10:30

Central square 2 (C2)

Deborah Louise Sinclair

Oral presentation

Determinants of recovery capital among persons in early and stable recovery from drug addiction

09:00 to 10:30

Central square 2 (C2)

Wouter Vanderplasschen

10:50

Oral presentation

3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway

10:50 to 12:20

Insights zone 4 (I4)

Gabrielle K. Welle-Strand

Oral presentation

1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences

4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK

5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.

2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe

What would it take to get people to stop rolling joints with tobacco?

Personas in drug use - Understanding substance-use motives in young adults

Data mining-based profiles of emerging adults at elevated risk for negative alcohol use consequences

Strategic Ignorance or Counter Knowledge: 60 years of Harm Reduction Debates in Swedish Parliament

1. Socioeconomic status, alcohol use and the mediating role of social support and neighbourhood disadvantage among individuals meeting criteria for a mental health problem: a cross-sectional study

10:50 to 12:20

Knowledge market 2 (K2)

Jo-Anne Puddephatt

Oral presentation

2. The association between mental health and alcohol use in racial and ethnic groups: A secondary data analysis across studies

10:50 to 12:20

Knowledge market 2 (K2)

Laura Goodwin

Oral presentation

3. Association of psychological distress with smoking cessation, duration of smoking abstinence and use of other nicotine-containing products: A cross-sectional population survey in Great Britain

10:50 to 12:20

Knowledge market 2 (K2)

Leonie Brose

Oral presentation

4. Can we make cannabis safer? An experimental study of four CBD: THC rations in healthy volunteers

10:50 to 12:20

Knowledge market 2 (K2)

Amir Englund

Oral presentation

Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.

10:50 to 12:20

Knowledge market 3 (K3)

Sarah Larney

Oral presentation

Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.

10:50 to 12:20

Knowledge market 3 (K3)

Anna Hernández-Rubio

Oral presentation

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.

10:50 to 12:20

Knowledge market 3 (K3)

Nicola Jones

Oral presentation

Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK

10:50 to 12:20

Knowledge market 3 (K3)

Andrew McAuley

Oral presentation

The development of a disclaimer to accompany marketing and recruitment efforts for gambling products

An online gambling intervention using the realization effect

Consumer Protection and Responsible Gambling Practices in Crypto Casinos

The utility of different values frameworks for drug policy analysis

10:50 to 12:20

Knowledge market 1 (K1)

Alison Ritter

Oral presentation

Why did New Zealand’s referendum to legalise recreation cannabis fail? An analysis of media campaigns and predictors of voter support for cannabis legalisation in New Zealand

10:50 to 12:20

Knowledge market 1 (K1)

Marta Rychert

Oral presentation

Language matters and it starts with us: How to talk about drugs to advocate for reform more effectively

10:50 to 12:20

Knowledge market 1 (K1)

Alice Salomon

Oral presentation

The Policy Constellation Approach: application of a critical realist public policy theory to the explanation of the UK’s drug strategy for 2021-2031

10:50 to 12:20

Knowledge market 1 (K1)

Alex Stevens

Oral presentation

Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork

10:50 to 12:20

Central square 3 (C3)

Fabrice Guilbaud

Oral presentation

New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain

10:50 to 12:20

Central square 3 (C3)

Adrià Quesada

Oral presentation

5. Drug use among non-binary persons in Europe: findings from a web survey

10:50 to 12:20

Networking zone 3 (N3)

Cristiana Vale Pires

Oral presentation

1. What is gender and why it is necessary to incorporate a gender perspective in the drug field? Evolution of key theoretical concepts in the area of gender and trends influencing the drug field

10:50 to 12:20

Networking zone 3 (N3)

Analia Torres

Oral presentation

2. Gender differences in drug use from a social perspective

10:50 to 12:20

Networking zone 3 (N3)

Nuria Romo

Oral presentation

3. Sex differences in drug use and drug addiction from a neuroscience perspective

10:50 to 12:20

Networking zone 3 (N3)

Anne Marije Kaag

Oral presentation

4. Using an intersectional risk environment approach to understand health and drug outcomes: Looking across social locations

10:50 to 12:20

Networking zone 3 (N3)

Alexandra B. Collins

Oral presentation

6. Implementing a gender dimension in drug policy and practice: findings from the Pompidou Group handbook for practitioners and decision makers

10:50 to 12:20

Networking zone 3 (N3)

Sarah Morton

Oral presentation

Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021

10:50 to 12:20

Central square 3 (C3)

Ruben Vrolijk

Oral presentation

Shifting stages of ATS use and evidence-based intervention for risk reduction

10:50 to 12:20

Central square 3 (C3)

Nienke Liebregts

Oral presentation

Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.

10:50 to 12:20

Central square 3 (C3)

Ruben Van Beek

Oral presentation

4. Drug consumption rooms in Lisbon: lessons learned

10:50 to 12:20

Central square 2 (C2)

Adriana Curado

Oral presentation

5. A strategy for all drug uses

10:50 to 12:20

Central square 2 (C2)

Maria Carmo Carvalho

Oral presentation

Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort

10:50 to 12:20

Central square 1 (C1)

Torill Tverborgvik

Oral presentation

All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)

10:50 to 12:20

Central square 1 (C1)

Ragnhild Jamt

Oral presentation

The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision

10:50 to 12:20

Central square 1 (C1)

Steven Belenko

Oral presentation

(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews

10:50 to 12:20

Central square 1 (C1)

Nicky Dirkx

Oral presentation

Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries

10:50 to 12:20

Central square 1 (C1)

Sara Mazzilli

Oral presentation

3. Harm Reduction and Public Health: The place of 'subjugated knowledges'

10:50 to 12:20

Central square 2 (C2)

Daniel Martins

Oral presentation

1. How to reduce drug-related crimes

10:50 to 12:20

Central square 2 (C2)

Jorge Quintas

Oral presentation

2. 20 years of Portuguese drug policy: developments and current challenges

10:50 to 12:20

Central square 2 (C2)

Ximene Rêgo

Oral presentation

The needs of professionals working on sexualized substance use and its implications for health and social services

10:50 to 12:20

Knowledge market 4 (K4)

Jorge Flores-Aranda

Oral presentation

PnP/CHEMSEX a means of surviving post-migration

10:50 to 12:20

Knowledge market 4 (K4)

Alexandre Brulotte

Oral presentation

Don’t cure, but care': affirmative intervention amongst men of sexual and gender diversity in the context of chemsex

10:50 to 12:20

Knowledge market 4 (K4)

Yannick Gaudette

Oral presentation

Identity matters in understanding gay and bisexual men's injecting drug use: a grounded theory study

10:50 to 12:20

Knowledge market 4 (K4)

Sophia Elvira Schroeder

Oral presentation

Interpersonal needs of gay, bisexual, and other msm who practice sexualized substance use: a critical component in treating substance use disorders among sexual minorities

10:50 to 12:20

Knowledge market 4 (K4)

Joseph De Piano

Oral presentation

1. An insight into alcohol, tobacco, drug, gambling and gaming in the Mediterranean Region: socioeconomic, policy context and patterns of use among adolescents

10:50 to 12:20

Networking zone 4 (N4)

Elisa Benedetti

Oral presentation

2. Gaming, gambling and social media use among Egyptian adolescents

10:50 to 12:20

Networking zone 4 (N4)

Nermin Shaker

Oral presentation

3. Adolescent substance use and risk behaviours in Morocco: results and indications for prevention

10:50 to 12:20

Networking zone 4 (N4)

Jallal Toufiq

Oral presentation

4. Gender differences and trends in substance use among Tunisian adolescent students

10:50 to 12:20

Networking zone 4 (N4)

Hajer Aounallah-Skhiri

Oral presentation

2. Changing risk perception on alcohol consumption

10:50 to 12:20

Main stage

Carina Ferreira-Borges

Oral presentation

3. The Gut-Brain Axis in AUD - still valid?

1. Presentation of the project "Alcohol no ordinary commodity (ANOC) vx 3"

Optimising digital tools for substance use and substance use disorders by 2030: a backcasting exercise

10:50 to 12:20

Insights zone 1 (I1)

Elsa Caballeria, AbuTaher AbuTaher, Florian Scheibein

Oral presentation

European Web Survey on Drugs

10:50 to 12:20

Central square 4 (C4)

João Matias, José Pedro Teixeira

Oral presentation

European Web Survey on Drugs - Luxembourg

10:50 to 12:20

Central square 4 (C4)

Rita Cardoso Seixas

Oral presentation

European Web Survey on Drugs - Ireland

10:50 to 12:20

Central square 4 (C4)

Nicki Killeen

Oral presentation

The experience of running web surveys in Belgium

10:50 to 12:20

Central square 4 (C4)

Elena Damian

Oral presentation

Web surveys on drugs - how can these be important for those who use drugs

10:50 to 12:20

Central square 4 (C4)

Lígia Parodi

13:20

Oral presentation

Monitoring online illicit drug market during the COVID-19 in Georgia

Who buys drugs using online sources in Ireland? Findings from the European Web Survey on Drugs

Brokered Illegal Drug Sales as a Measure of Local Demand

1. EU Xchange prevention registry: targeting common risk factors as a win-win in drug and crime prevention

4. Promoting professional behaviour change in prevention and health promotion

13:20 to 14:50

Insights zone 2 (I2)

Maximilian von Heyden

Oral presentation

3. Positive youth development as an agenda for cross-domain prevention: a scoping review of concepts, methods, and effects

Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.

13:20 to 14:50

Knowledge market 2 (K2)

John Robins

Oral presentation

Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.

13:20 to 14:50

Knowledge market 2 (K2)

Ena Lynn

Oral presentation

Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study

13:20 to 14:50

Knowledge market 2 (K2)

Suzi Lyons

Oral presentation

Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project

13:20 to 14:50

Knowledge market 2 (K2)

Laurent Michel

Oral presentation

The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa

13:20 to 14:50

Knowledge market 2 (K2)

Nirvana Morgan

Oral presentation

4. Understanding the mechanisms that link childhood stress with risk of addiction

13:20 to 14:50

Central square 4 (C4)

Molly Carlyle

Oral presentation

5. Is opioid liking driven by relief or reward? Evidence from clinical and experimental studies of acute stress

13:20 to 14:50

Central square 4 (C4)

Isabell M. Meier

Oral presentation

1. Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users

13:20 to 14:50

Central square 4 (C4)

Boris Quednow

Oral presentation

2. The endocannabinoid system and drug addiction: basal and stress-related endocannabinoid plasma levels in chronic cocaine users and prescription opioid users

13:20 to 14:50

Central square 4 (C4)

Sara Kroll

Oral presentation

3. The endocannabinoid system as a potential buffer against the development of a substance use disorder following childhood trauma exposure

13:20 to 14:50

Central square 4 (C4)

Leah M. Mayo

Oral presentation

Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?

13:20 to 14:50

Knowledge market 3 (K3)

Øystein Bruun Ericson

Oral presentation

Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance

13:20 to 14:50

Knowledge market 3 (K3)

Alexander Walley

Oral presentation

The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes

13:20 to 14:50

Knowledge market 3 (K3)

Paul Dietze

Oral presentation

Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts

13:20 to 14:50

Knowledge market 3 (K3)

Nanor Minoyan

Oral presentation

Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia

13:20 to 14:50

Knowledge market 1 (K1)

Luis Felipe Cruz-olivera

Oral presentation

Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users

13:20 to 14:50

Knowledge market 1 (K1)

Robert Stirling

Oral presentation

Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach

13:20 to 14:50

Knowledge market 1 (K1)

Stijn Hoorens

Oral presentation

Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers

13:20 to 14:50

Knowledge market 1 (K1)

Caitlin Hughes

Oral presentation

2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting

The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map

13:20 to 14:50

Knowledge market 1 (K1)

Eric Sevigny

Oral presentation

3. The international guidance on harm reduction interventions in prisons

5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation

4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons

1. Provision of harm reduction interventions in European prisons: short overview of available services

Substance-related Consequences, Dependence and Substance Use Disorder: Promising new model taking clinical and statistical points of view into consideration

13:20 to 14:50

Central square 1 (C1)

Rosalie Genois

Oral presentation

3. Navigating an emergency response and collective action on the fentanyl frontlines: An ethnographic study of overdose prevention site implementation in Vancouver, Canada’s Downtown Eastside

13:20 to 14:50

Central square 2 (C2)

Ryan McNeil

Oral presentation

1. Drug consumption rooms: welfare state and social acceptance in France

13:20 to 14:50

Central square 2 (C2)

Marie Jauffret-Roustide

Oral presentation

2. Drug consumption rooms in Denmark: attitudes and experiences from local residents

13:20 to 14:50

Central square 2 (C2)

Esben Houborg

Oral presentation

Prevention and Treatment of hazardous Substance Use among Refugees: Perspectives from Germany

13:20 to 14:50

Central square 3 (C3)

Marion Laging

Oral presentation

Psychosocial functions of drug using and selling among young persons in Malmö who came to Sweden as unaccompanied refugee minors

13:20 to 14:50

Central square 3 (C3)

Anke Stallwitz

Oral presentation

Re-visioning from risk and safety to survival and wellness; behaviours among people who use methamphetamine with opioids in British Columbia, Canada

13:20 to 14:50

Central square 3 (C3)

Jessica Xavier

Oral presentation

Indigenous Peoples experiences with overdose and response in Vancouver, Canada's Downtown Eastside

13:20 to 14:50

Central square 3 (C3)

Jennifer Lavalley

Oral presentation

Language and concepts in alcohol use disorder: how framing affects stigma and recovery

13:20 to 14:50

Central square 1 (C1)

James Morris

Oral presentation

Watch out for the boogieman': multiple stigma and recovery experiences of ethnic minorities with substance use problems

13:20 to 14:50

Central square 3 (C3)

Aline Pouille

Oral presentation

Drinking patterns across Europe. Do beverage preferences matter?

13:20 to 14:50

Central square 1 (C1)

Janusz Sieroslawski

Oral presentation

Emerging Issues in the Management of Conflict of Interest

13:20 to 14:50

Central square 1 (C1)

Matej Košir

Oral presentation

Reproducibility and translation in addiction research

13:20 to 14:50

Central square 1 (C1)

Rainer Spanagel

Oral presentation

2. The experience of persons in homeless situation with alcohol related problems regarding a pharmacological harm reduction initiative

13:20 to 14:50

Knowledge market 4 (K4)

Raquel Medinas

Oral presentation

4. The role of those without a role - The perspective of non-clinical professionals in emergencyshelters on how to manage alcohol use disorder - police, security agents and cleaning staff

13:20 to 14:50

Knowledge market 4 (K4)

Ricardo Fuertes

Oral presentation

3. Amidst the most vulnerable voices: women and migrants in homeless situation with Alcohol UseDisorders (AUD)

13:20 to 14:50

Knowledge market 4 (K4)

Màrio Santos

Oral presentation

1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial

13:20 to 14:50

Networking zone 3 (N3)

Thomas Phillips

Oral presentation

5. All we can do - Emergency Shelter' staff positioning regarding alcohol related problems in thecontext of a new harm reduction intervention

13:20 to 14:50

Knowledge market 4 (K4)

Joana Tavares

Oral presentation

2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial

13:20 to 14:50

Networking zone 3 (N3)

Paolo Deluca

Oral presentation

3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation

13:20 to 14:50

Networking zone 3 (N3)

Amy Wolstenholme

Oral presentation

1. Individuals with lived experience of homelessness and alcohol use disorders - insights from the PLACE study

13:20 to 14:50

Knowledge market 4 (K4)

Ana Neto